On the stock market since 2007, it operates in the world of health and science. It has 231 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $318.1M in the vault; even if every debt were paid off, $300.2M would remain.
A loss of $105.0M against $0 in annual sales. And on top of that, sales fell from the year before.
The stock trades 11% above the average analyst price target.
On our five-subject report card, CAPR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CAPR is a high-risk stock — not yet profitable, and its future rides on its product catching on.